Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

EPO-906 (Novartis).

Carlos María Galmarini1, Charles Dumontet

  • 1University Lyon, INSERM 590, 8 Avenue Rockefeller, 69373 Lyon, France. fgalma@rockefeller.univ-lyon1.fr

Idrugs : the Investigational Drugs Journal
|December 11, 2003
PubMed
Summary

Novartis Pharma AG is developing EPO-906, an intravenous microtubule stabilizer, for cancer treatment. This novel formulation targets microtubule depolymerization to combat cancerous cell growth.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

3D bioprinting for cancer modeling and drug screening.

Biomarker research·2026
Same author

When more target antigen expression is less.

Cancer cell·2026
Same author

Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges.

Cell·2026
Same author

Fibrillarin Contributes to the Oncogenic Characteristics of Colorectal Cancer Cells and Reduces Sensitivity to 5-Fluorouracil.

Cancers·2025
Same author

Whole-Exome Sequencing-Based Linkage Analysis of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS) Pedigrees.

Cancers·2025
Same author

Beyond Rodents: Alternative Animal Models in Colorectal Cancer Research.

International journal of molecular sciences·2025

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Cancer remains a leading cause of mortality worldwide.
  • Microtubules are crucial for cell division and are a validated target for cancer therapy.
  • Existing therapies face challenges with efficacy and resistance.

Purpose of the Study:

  • To introduce EPO-906, an investigational intravenous formulation.
  • To characterize EPO-906 as a microtubule depolymerization inhibitor.
  • To evaluate the potential of EPO-906 in cancer treatment.

Main Methods:

  • EPO-906 is an intravenous formulation.
  • The drug functions as a microtubule stabilizer, inhibiting depolymerization.
  • Preclinical studies are underway to assess efficacy.

Main Results:

  • EPO-906 demonstrates potential as a novel anti-cancer agent.
  • The drug's mechanism involves stabilizing microtubules.
  • Further clinical evaluation is warranted.

Conclusions:

  • EPO-906 represents a promising new therapeutic candidate for cancer.
  • Its mechanism of action as a microtubule stabilizer offers a novel approach.
  • Novartis Pharma AG is advancing this compound for clinical development.

Related Experiment Videos